Panacea Acquisition II ^{Priced, Nasdaq: PANA}

We are a newly incorporated blank check company. While we may pursue an initial business combination opportunity in any industry or geographical location, we intend to capitalize on our management team’s background and experience to identify innovative companies in the biotechnology sector that are domiciled in North America or Europe. Our sponsor is an affiliate of EcoR1, an investment firm with over $2.7 billion in regulatory assets under management as of December 31, 2020. EcoR1 was established in March 2013 by our Chief Executive Officer, Oleg Nodelman, and is focused on therapeutic companies within the biotechnology sector. We believe the experience of our team, strengthened by their industry network and our experienced board of directors, will enhance our management team’s ability to source viable prospective target businesses, capitalize them and ensure public-market readiness. We believe that our management team is equipped with the knowledge, experience, capital and human resources to pursue unique opportunities that will offer attractive risk-adjusted returns.